Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hereditary Peripheral Neuropathy”

808 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 808 results

Early research (Phase 1)Ended earlyNCT02292225
What this trial is testing

Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

Who this might be right for
Lymphocytic Leukemia, ChronicLymphoma, Small Lymphocytic
SecuraBio 3
Testing effectiveness (Phase 2)Study completedNCT04396496
What this trial is testing

Treatment of POEMS Syndrome With Daratumumab

Who this might be right for
POEMS Syndrome
University of Arkansas 2
Large-scale testing (Phase 3)Study completedNCT01994889
What this trial is testing

Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy

Who this might be right for
Transthyretin (TTR) Amyloid Cardiomyopathy
Pfizer 441
Not applicableUnknownNCT05701397
What this trial is testing

Prevalence of Cardiac Amyloidosis in Patients Undergoing Surgery for Lumbar Spinal Stenosis.

Who this might be right for
Cardiac AmyloidosisSpinal Stenosis
Steen Hvitfeldt Poulsen 200
Not applicableUnknownNCT01777451
What this trial is testing

Whole Body Magnetic Resonance Imaging With Diffusion Weighted Imaging : Potential Role in Neurofibromatosis

Who this might be right for
Whole Body ImagingMagnetic Resonance ImagingNeurofibromatosis 1+2 more
Universitaire Ziekenhuizen KU Leuven 30
Not applicableNo Longer AvailableNCT03317366
What this trial is testing

Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies

Who this might be right for
Proteus SyndromePIK3CA-Related Overgrowth Spectrum (PROS)Growth Disorders
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Early research (Phase 1)Ended earlyNCT04800822
What this trial is testing

PF-07284892 in Participants With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Pfizer 53
Testing effectiveness (Phase 2)Study completedNCT00846430
What this trial is testing

Medical Treatment of "High-Risk" Neurofibromas

Who this might be right for
Neurofibromatosis 1
Corewell Health West 9
Not applicableStudy completedNCT05795400
What this trial is testing

Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy

Who this might be right for
Heart Failure With Reduced Ejection FractionHeart Failure With Preserved Ejection FractionHeart Failure With Mid Range Ejection Fraction+1 more
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation 50
Testing effectiveness (Phase 2)Study completedNCT01733407
What this trial is testing

L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1

Who this might be right for
Hereditary Sensory and Autonomic Neuropathy Type I
Massachusetts General Hospital 18
Large-scale testing (Phase 3)Study completedNCT01886495
What this trial is testing

Effect of High Protein Diet on Adiponectin and Inflammation Among Overweight and Obese Children

Who this might be right for
Body Mass Index Quantitative Trait Locus 5 DisorderTangier Disease
Isfahan University of Medical Sciences 50
Not applicableLooking for participantsNCT06866912
What this trial is testing

Observational Epidemiological Study of Patients Suffering From Systemic Amyloidosis

Who this might be right for
Cardiomyopathy
IRCCS Azienda Ospedaliero-Universitaria di Bologna 750
Very early researchStudy completedNCT01275586
What this trial is testing

Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Who this might be right for
NeurofibromatosisNF1Neurofibromas
Indiana University 6
Not applicableStudy completedNCT01595139
What this trial is testing

MicroRNAs in Patients With Neurofibromatosis Type 1

Who this might be right for
GliomaNeurofibromatosis Type 1
Ann & Robert H Lurie Children's Hospital of Chicago 9
Testing effectiveness (Phase 2)Looking for participantsNCT04750928
What this trial is testing

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

Who this might be right for
Neurofibromatosis 1
National Cancer Institute (NCI) 55
Not applicableLooking for participantsNCT07196839
What this trial is testing

Determining the Association of TTR Stabilizing Therapy With Circulating TTR Amyloid Aggregates Over Time in Patients With ATTR-CM: Longitudinal Biomarker Study

Who this might be right for
Transthyretin (TTR) Amyloid Cardiomyopathy
University of Texas Southwestern Medical Center 50
Not applicableStudy completedNCT04862273
What this trial is testing

CMR T1 Mapping for Diagnosis of Cardiac Amyloidosis

Who this might be right for
Heart Failure NYHA Class IIHeart Failure NYHA Class IIIHeart Failure NYHA Class IV+4 more
University of Leipzig 112
Testing effectiveness (Phase 2)Study completedNCT02595983
What this trial is testing

The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant

Who this might be right for
Transthyretin (TTR)-Mediated AmyloidosisFamilial Amyloidotic Polyneuropathy (FAP)ATTR Amyloidosis+1 more
Alnylam Pharmaceuticals 12
Not applicableUnknownNCT05940922
What this trial is testing

RWE-based Treatment Patterns and Outcomes in CIDP

Who this might be right for
Chronic Inflammatory Demyelinating PolyneuropathyGuillain-Barre SyndromeHereditary Amyloidosis
RwHealth 170
Testing effectiveness (Phase 2)Active Not RecruitingNCT02407405
What this trial is testing

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Who this might be right for
Neurofibromatosis 1 (NF1)Plexiform Neurofibromas (PN)
National Cancer Institute (NCI) 36
Load More Results